Beijing B3R Pharmaceutical Technology HK Limited

The primary objective of this study was to evaluate the safety and tolerability of ricolinostat in patients with signs and symptoms of CIPN. The exploratory objective was to evaluate the effect of ricolinostat treatment on the clinical manifestations of CIPN and IENFD.

Primary objective: To evaluate the safety of a single oral dose of 120 mg (10 mg/mL) of Ricolinostat in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of parent drug and metabolites (ACY-344 and ACY-349) of Ricolinostat in healthy Chinese adult subjects after a single oral dose.